Natalija Novak's research while affiliated with University of Bonn and other places

... This review examines the methods employed in diagnosing monkeypox and associated challenges. The initial diagnosis of Mpox is often based on clinical evaluation by healthcare professionals [73]. This involves assessing the patient's medical history, symptoms, and physical examination, particularly the presence of characteristic skin lesions at different stages (macules, papules, vesicles, and pustules) and the distribution pattern. ...

... Possible reasons for early discontinuation could be (1) displeasure with local adverse reactions; (2) inconvenience of taking a daily treatment; (3) lack of perception of adequate clinical benefit; (4) need for better education and understanding of potential adverse events; (5) less frequent education, understanding of potential adverse effects, and follow-up than in clinical trials; and (6) cost of the medication. 13 However, the study's strength lies in the comprehensive administrative data programming that captured all coded relevant adverse diagnostic events, hospitalizations, emergency department care, urgent care visits, and dispensed epinephrine. Use of the HDM SLIT-tablet was unrestricted, and our results are potentially more generalizable than those in clinical trials, which were encumbered by specific exclusions. ...

... [13][14][15] In particular, depigmented polymerized (DPP) allergen extracts can be prepared by treatment with mild acid (to remove low molecular weight compounds: depigmentation) and protein crosslinking with glutaraldehyde (polymerization); these extracts have been extensively characterized and approved for safe, effective SCIT and/or SCIT in allergic respiratory diseases induced by birch pollen, grass pollen, and house dust mite aeroallergens. 10,[16][17][18][19][20][21][22][23][24][25] Prior to the study, the DPP birch pollen extract for SCIT investigated here had been marketed in Germany at doses of up to and including 1000 DPP/mL (corresponding to~60 μg Bet v 1/mL prior to depigmentation). 10,[22][23][24] The Phase II study described here was part of the clinical development of a DPP birch pollen formulation under the German Therapy Allergen Ordinance. ...

... AD is the most frequent skin disease during the first and second trimesters of pregnancy. The onset or the recurrence of AD during gestation is called ''atopic eruption of pregnancy'' and should be distinguished from other pruritic eruptions (174). JAKis, including UPA, BAR e ABR, are contraindicated in pregnancy and breastfeeding based on animal studies that showed teratogenic effects (51)(52)(53). ...

... This suggests that commercially formulated mRNA vaccines caused severe side effects in mice while SA-modified mRNA vaccine significantly reduced these side effects. The reduction in side effects may be attributed to using cleavable mPEG 2000 CHS since it has been reported that PEG 2000 -lipid conjugate could contribute to allergic reactions associated with SARS-Cov-2 mRNA vaccines rather than native PEG [33]. The reported cases of hypocomplementemic urticarial vasculitis following SARS-CoV-2 mRNA vaccination have been associated with amplification of TNF-α, IL-1, and IL-6 [34]. ...

... Because the immune system triggers inflammation as an innate response to foreign particles, there is an overlap between the consequences of irregularity in the immune system and the inflammatory response. For instance, T cell populations on the skin, even rare ones like γδ T cells, have a specific role in allergic skin inflammation and in maintaining tissue homeostasis [75,76]. Effector T cells and memory T cells are accompanied by natural killer cells and T cells expressing MHCR on the skin. ...

... Consequently, our murine model not only provides a partial understanding of the pathomechanisms underlying allergic asthma in humans, but also a starting point for development of a peanut-allergen-associated mouse model. Given the lack of curative treatment options, the increasing prevalence, and a high socioeconomic burden associated with frequent emergency admissions, novel therapy options are urgently needed (54). Recently, oral immunotherapy (OIT) has been recommended as a potential treatment option for peanut allergy (55,56). ...